Luca Benatti, President and Chief Executive Officer, and Stan Musial, Chief Financial Officer, will participate in the JMP Life Sciences Conference on Wednesday, June 19, 2019, at the St. Regis New York. The Company is scheduled to present at the conference at 1:30.
EryDel Appoints Alyssa Wyant as Senior Vice President, Regulatory Affairs.
EryDel received the 2018 most innovative company Startup Italia Award on occasion of the Open Summit 2018 that took place in Milano on 17 December.
EryDel Appoints Stan Musial as Chief Financial Officer
EryDel appoints Ronan Gannon as Chief Commericial Officer
EryDel-Orphan Technologies signing a licensing and supply agreement
EryDel to present at the UBS Global Healthcare Conference 2018
EryDel Raises Euro 26.5 Million in Financing
EryDel Appoints Guenter R Janhofer, MD, as Chief Medical Officer
EryDel announced the initiation of the Ataxia Telangiectasia Trial with the EryDex System (ATTEST) study
EryDel Consortium gains Euro 6 million Funding for development of EDS for the treatment of Ataxia Telangiectasia
Long term benefit of erytrocyte-delivered dexamathasone in Ataxia Telangiectasia
EryDel expands Series B financing to 29.5M
Phase II results in Ataxia Telangiectasia published in Orphanet Journal of Rare Diseases
EryDel selected as one of the top five candidates in 2013 EuropaBio Most Innovative EU Biotech SME Award
Enzyme-loaded erythrocytes restore normal blood concentrations of Phenylalanine in a mouse model of Phenylketonuria (PKU)
EryDel SpA Completes €15 Million Series B financing
EryDel SpA Announces EMA Orphan Drug Designation for EryDex for the treatment of Ataxia Telangiectasia
EryDel announces US IND approval for EryDex
Data on Magnetic Red Blood Cells (RBCs) as new contrast agents for Magnetic Resonance Imaging (MRI) applications to be presented at SPIE Medical Imaging Annual Meeting 2013
Journal of Biological Chemistry publication highlights molecular mechanism for EryDex effect on Ataxia Telangiectasia-mutated (ATM) protein
EryDel SpA Announces FDA Orphan Drug Designation for EryDex for the treatment of Ataxia Telangiectasia.
EryDel announces the appointment of the Company CEO.
EryDel announces Positive Results with EryDex in patients with Ataxia Telangiectasia.
Significant benefit seen on Primary and Secondary end-points.
EryDel has CE Marked its New Medical Devices for automatic encapsulation of Drugs into Human Autologous Red Blood Cells